6Albanese A, Barnes MP, Bhatia KP, et al. A systematic review on the diagnosis and treatment of primary ( idiopathic ) dystonia and dystonia plus syndromes: report of an EFNS/MDS-ES Task Force[J]. Eur J Neurol, 2006, 13(5) :433 -444.
7Jankovic J. Treatment of dystonia[ J]. Lancet Neurol, 2006, 5 (10) :864 -872.
8Papapetropoulos S, Singer C. Botulinum toxin in movement disorders[J]. Semin Neurol, 2007, 27(2) :183 -194.
3Inzelberg R, Nisipeanu P, Schechtman E. Practice parameter :initiation of treatment for Parkinson's disease:an evidence-based review[J]. Neurology ,2002 ,59 (8) :1292-1292.
4Olanow CW, Watts RL, Koller WC. An algorithm (decision tree) for the management of Parkinson disease(2001): treatment guidelines [J]. Neurology ,2001,56(suppl 5): S1-88.
5Bonneville F, Welter ML, Elie C, et al. Parkinson disease, brain volumes, and subthalamic nucleus stimulation[J]. Neurology, 2005 , 64(9):1598-1604.
6Prasad KN, Kumar B, Yan XD, et al. Alpha-Tocopheryl succinate, the most effective form of Vitamin E for adjuvant cancer treatment: A Review[J]. J Am Coll Nutr,2003,22(2):108-117.
7Stocchi F. The levodopa wearing-off phenomenon in Parkinson's disease: pharmacokinetic considerations[J]. Expert Opin Pharmacother, 2006, 7(10):1399-1407.
8王永炎.中医内科学[M].上海:上海科学技术出版社,1996.167～172
9Demirkiran M,Jankovic J. Paroxysmal dyskinesias., clinical features and classification[J]. Ann Neurol, 1995,38 : 571.
10Jankovic J,Demirkiran M. Kinesigenic paroxysmal hemiyskine- sias[J]. Ann Med Sci, 2001,10 : 92.
